|
1
|
Keating MJ: Chronic lymphocytic leukemia.
Semin Oncol. 26:107–114. 1999.
|
|
2
|
Catovsky D, Richards S, Matutes E, et al
UK National Cancer Research Institute (NCRI); Haematological
Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia
Working Group: Assessment of fludarabine plus cyclophosphamide for
patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a
randomised controlled trial. Lancet. 370:230–239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hallek M, Fischer K, Fingerle-Rowson G, et
al International Group of Investigators; German Chronic Lymphocytic
Leukaemia Study Group: Addition of rituximab to fludarabine and
cyclophosphamide in patients with chronic lymphocytic leukaemia: a
randomised, open-label, phase 3 trial. Lancet. 376:1164–1174. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tam CS, O’Brien S, Wierda W, et al:
Long-term results of the fludarabine, cyclophosphamide, and
rituximab regimen as initial therapy of chronic lymphocytic
leukemia. Blood. 112:975–980. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bosch F, Abrisqueta P, Villamor N, et al:
Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new,
highly active chemoimmunotherapy regimen for chronic lymphocytic
leukemia. J Clin Oncol. 27:4578–4584. 2009. View Article : Google Scholar
|
|
6
|
Duke VM, Gandini D, Sherrington PD, et al:
V(H) gene usage differs in germline and mutated B-cell chronic
lymphocytic leukemia. Haematologica. 88:1259–1271. 2003.PubMed/NCBI
|
|
7
|
Del Poeta G, Maurillo L, Venditti A, et
al: Clinical significance of CD38 expression in chronic lymphocytic
leukemia. Blood. 98:2633–2639. 2001.PubMed/NCBI
|
|
8
|
Del Principe MI, Del Poeta G, Buccisano F,
et al: Clinical significance of ZAP-70 protein expression in B-cell
chronic lymphocytic leukemia. Blood. 108:853–861. 2006.
|
|
9
|
Hallek M, Cheson BD, Catovsky D, et al
International Workshop on Chronic Lymphocytic Leukemia: Guidelines
for the diagnosis and treatment of chronic lymphocytic leukemia: a
report from the International Workshop on Chronic Lymphocytic
Leukemia updating the National Cancer Institute-Working Group 1996
guidelines. Blood. 111:5446–5456. 2008. View Article : Google Scholar
|
|
10
|
Leporrier M, Chevret S, Cazin B, et al
French Cooperative Group on Chronic Lymphocytic Leukemia:
Randomized comparison of fludarabine, CAP, and ChOP in 938
previously untreated stage B and C chronic lymphocytic leukemia
patients. Blood. 98:2319–2325. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Byrd JC, Peterson BL, Morrison VA, et al:
Randomized phase 2 study of fludarabine with concurrent versus
sequential treatment with rituximab in symptomatic, untreated
patients with B-cell chronic lymphocytic leukemia: results from
Cancer and Leukemia Group B9712 (CALGB 9712). Blood. 101:6–14.
2003. View Article : Google Scholar
|
|
12
|
Guarini A, Gaidano G, Mauro FR, et al:
Chronic lymphocytic leukemia patients with highly stable and
indolent disease show distinctive phenotypic and genotypic
features. Blood. 102:1035–1041. 2003. View Article : Google Scholar
|
|
13
|
Wierda WG, O’Brien S, Wang X, et al:
Prognostic nomogram and index for overall survival in previously
untreated patients with chronic lymphocytic leukemia. Blood.
109:4679–4685. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huhn D, von Schilling C, Wilhelm M, et al:
Rituximab therapy of patients with B-cell chronic lymphocytic
leukemia. Blood. 98:1326–1331. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
O’Brien SM, Kantarjian H, Thomas DA, et
al: Rituximab dose-escalation trial in chronic lymphocytic
leukemia. J Clin Oncol. 19:2165–2170. 2001.PubMed/NCBI
|
|
16
|
Schlette EJ, Admirand J, Wierda W, et al:
p53 expression by immunohistochemistry is an important determinant
of survival in patients with chronic lymphocytic leukemia receiving
frontline chemo-immunotherapy. Leuk Lymphoma. 50:1597–1605. 2009.
View Article : Google Scholar
|
|
17
|
Altekruse SF, Kosary CL, Krapcho M, et al
National Cancer Institute: SEER Cancer Statistics Review,
1975–2007. http://seer.cancer.gov/csr/1975_2007.
Accessed July 1, 2011.
|
|
18
|
Cheson BD: Infectious and
immunosuppressive complications of purine analog therapy. J Clin
Oncol. 13:2431–2448. 1995.PubMed/NCBI
|
|
19
|
Hamblin TJ, Orchard JA, Gardiner A, et al:
Immunoglobulin V genes and CD38 expression in CLL. Blood.
95:2455–2457. 2000.PubMed/NCBI
|
|
20
|
Rassenti LZ, Jain S, Keating MJ, et al:
Relative value of ZAP-70, CD38, and immunoglobulin mutation status
in predicting aggressive disease in chronic lymphocytic leukemia.
Blood. 112:1923–1930. 2008. View Article : Google Scholar : PubMed/NCBI
|
